Ipsen Receives European Green Light for Pediatric Brain Tumor Treatment
The European Commission has granted conditional marketing authorization to Ipsen's Ojemda (tovorafenib) for treating children with pediatric low-grade gliomas presenting a BRAF alteration and having progressed after previous treatments. This approval applies to the 27 EU member states, as well as Iceland, Liechtenstein, and Norway.
The European Commission's authorization is based on data from the phase II pivotal FIREFLY-1 study, which evaluated tovorafenib in 137 children and young adults with pediatric low-grade gliomas with BRAF alteration, who were relapsed or refractory, having received at least one prior systemic treatment. Tovorafenib is a type II RAF kinase inhibitor targeting mutated BRAF V600, wild-type BRAF, and wild-type CRAF. It acts on signaling pathways that regulate cell growth and division.
Impact on Pediatric Low-Grade Glioma Patients
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Over 800 children are diagnosed each year with pediatric low-grade glioma presenting a BRAF alteration in the European Union. Although classified as a slow-progressing low-grade tumor, this disease imposes a significant lifelong burden, often leading to severe physical and neurological impairments, including loss of vision, speech disorders, and motor dysfunctions. Until now, many affected children have had to undergo invasive surgeries, multiple lines of chemotherapy, and radiotherapy, often associated with long-term health complications. Sandra Silvestri, Executive Vice President and Chief Medical Officer at Ipsen, stated that 'the priority now is to ensure as rapid access as possible to this treatment for eligible children across Europe.'
SectorSanté · Vaccins et laboratoires de recherche›Industrie Pharmaceutique
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1074.9M€
Guidance from the release
Ipsen a réalisé un excellent début d'année 2026.
Croissance soutenue grâce aux trois aires thérapeutiques.
Risks mentioned
pression réglementaire anticipée sur de nouveaux médicaments
concurrence accrue sur Somatuline à cause des génériques
Opportunities identified
croissance des ventes totales du Groupe supérieure à 13,0 %
lancement de trois nouveaux programmes en phase avancée
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
